Most healthcare founders do not lose Round 2 on the pitch. They lose it on the model underneath the pitch. The seed deck sells a vision, and in a good market a vision was enough to clear the first institutional round. The Series B deck has to survive underwriting, and in 2026 the underwriting got a lot harder.
The numbers tell the story plainly. Of the companies that raised a $1M-plus seed round in 2023, only 24% have raised their next round. For the 2024 cohort, that figure is 16% (Crunchbase, May 2026). Raising a Series B today takes the kind of commercial traction that would have funded a Series C just three years ago (healthcare.digital, 2026). Round 2 stopped being a milestone you graduate to on schedule. It became a filter, and most decks are built for the milestone, not the filter.
The capital is there. U.S. digital health companies raised $7.4B across 244 deals in the first half of 2026, about $1B ahead of the same period a year earlier. But it is concentrating: mega-deals of $100M or more took 45% of all the capital invested, and the median deal size rose to $14M (Rock Health, H1 2026). Money is flowing to a smaller number of companies that can prove durability. That raises the bar for everyone else, it does not lower it.
What Round 2 actually underwrites
The single biggest shift is what investors are buying. Round 1 buys growth. Round 2 buys durable growth, and the two are not the same slide. The Rule of 40 still frames the conversation, but its internal weighting has moved hard toward the profit side. A credible, near-term path to profitability now carries more weight than a high growth rate on its own (Abacum, 2026).
In practical terms, most digital-health Series B rounds now expect $5M to $10M in ARR, 80% to 120% year-over-year growth, and a believable path to Rule-of-40 economics within roughly two years (healthcare.digital; New Market Pitch, 2026). Notice what that list is really asking for. It is not asking whether you grew. It is asking whether the growth is real, whether it holds, and whether it bends toward profit. Four patterns are where healthcare decks most often fail that test.
01. You pitched gross revenue, not net
In healthcare, booked revenue and collected revenue are two different numbers, and the gap between them is where a lot of decks quietly break. Gross-to-net adjustments, payer mix, contractual allowances, and denials all sit between the topline you present and the cash you actually keep. A Series B diligence team knows this, and one of the first things a sharp investor does is rebuild your revenue on a net basis.
If your deck leads with gross and the investor rebuilds it on net, every downstream number moves with it: growth rate, CAC payback, and valuation were all calculated on a topline the buyer just discounted. The fix is not spin. It is presenting net revenue from the start, so the story you tell and the number they rebuild are the same number.
02. There is no net revenue retention story
New logos are a sales result. Retention is a business result, and Round 2 pays for the second one. The metric that carries the most weight here is net revenue retention. Median NRR for private B2B SaaS runs around 106%, growth-stage investors treat 110% to 120% as the target, and vertical healthcare should beat the horizontal median rather than match it, because switching costs and workflow integration run deeper (SaaS Capital; Benchmarkit, 2025).
A deck that shows a wall of new-logo growth but cannot show a cohort retention curve reads as leaky, no matter how impressive the acquisition chart looks. If net revenue retention is below 100%, the existing base is shrinking on its own, and no growth rate fixes that multiple. If you cannot yet build the cohort view, that is itself the finding, and it is far better to discover it twelve months before the raise than to have a diligence team discover it for you.
03. CAC payback got hand-waved
A single blended customer-acquisition-cost slide is not an answer to the question Round 2 is asking. Investors want contribution margin and payback measured in months, broken out by segment, with evidence that the next dollar of acquisition spend still pays back on the same terms as the last one. Blended numbers hide the truth: a healthy segment can mask an unprofitable one, and a payback period that was fine at small scale can stretch as you push into harder channels.
If your payback is not expressed in months, it is not really a metric, it is a hope. The companies that clear Round 2 can show, by segment, how quickly a customer pays back the cost to acquire them, and that the unit economics hold as they scale rather than degrade.
04. Growth with no path to Rule of 40
The final pattern is a deck full of growth and empty of profitability logic. In the 2021 market, that was fundable. In 2026, investors are underwriting the path to Rule-of-40 economics, not just the promise of scale. They want to see the operating leverage: which costs are fixed, which scale sub-linearly with revenue, and when the lines cross into durable margin.
This does not mean you have to be profitable at Series B. It means you have to show, with a real operating model, how and when the business gets there. Growth without that arc reads as a company that has not yet done the finance work, and that is exactly the work Round 2 is testing for.
The quiet failure: the bridge that becomes a countdown
A weak Round 2 deck rarely fails loudly. More often it fails quietly, by turning into a bridge. Bridge rounds were under 10% of venture capital in the 2021 bull market. By 2025 they were 16.6%, and roughly 38% of seed-funded companies now raise a bridge before they ever price their next round (SeedScope; Value Add VC, 2026). The bridge went from a rescue to a routine.
A bridge is not automatically a failure. Tied to a specific, measurable fix with a written milestone and a date, it can be a smart use of capital that buys the six to twelve months needed to close a real gap. The danger is a bridge that only extends runway with no plan for what changes.
The fix: build the Round 2 model 12 to 18 months early
The through-line across all four patterns is the same. The deck is downstream of the model, and the model has to be built before you open the raise, not assembled the month you go to market. Twelve to eighteen months of lead time is what separates a company that sells Round 2 on its own terms from one that gets repriced by a diligence team. The work is concrete:
- Rebuild the topline on net revenue, with gross-to-net fully mapped, so the number you present is the number you keep.
- Build cohort-based net revenue retention, and know your gross and net retention by segment before an investor asks.
- Express CAC payback in months by segment, with contribution margin, and show that the next dollar still pays back.
- Write the operating model that shows a credible path to Rule-of-40 economics, with the cost lines that scale and the ones that do not.
- If a bridge is on the table, tie it to one written milestone and confirm current burn actually reaches it.
None of this is about hiding the flaws. It is about knowing them before the buyer does and having the answer ready. When the numbers and the story finally say the same thing, the raise gets easier, because you have removed the reasons an investor discounts you. That is a finance-seat problem, not a sales problem, and it is the work that turns a Round-2 filter into a Round-2 pass.